Advances in therapies for acute promyelocytic leukemia. - Wikidata - wikimedia - TriplyDB

Advances in therapies for acute promyelocytic leukemia.

Advances in therapies for acute promyelocytic leukemia.

http://www.wikidata.org/entity/Q37905921

about

Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells Arsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein Celastrol inhibits lung infiltration in differential syndrome animal models by reducing TNF-α and ICAM-1 levels while preserving differentiation in ATRA-induced acute promyelocytic leukemia cells Involvement of p38 in signal switching from autophagy to apoptosis via the PERK/eIF2α/ATF4 axis in selenite-treated NB4 cells p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells.Arsenic trioxide induces depolymerization of microtubules in an acute promyelocytic leukemia cell line.Arsenic exposure and DNA methylation among elderly men.RhoA modulates functional and physical interaction between ROCK1 and Erk1/2 in selenite-induced apoptosis of leukaemia cells.NLS-RARα Inhibits the Effects of All-trans Retinoic Acid on NB4 Cells by Interacting with P38α MAPK.p130Cas acts as survival factor during PMA-induced apoptosis in HL-60 promyelocytic leukemia cells.First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.Targeted therapy in rare cancers--adopting the orphans.Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis.Tetra-arsenic tetra-sulfide (As4S 4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis Quantitative proteomic analysis to decipher the differential apoptotic response of bortezomib-treated APL cells before and after retinoic acid differentiation reveals involvement of protein toxicity mechanisms.Bufalin induces the apoptosis of acute promyelocytic leukemia cells via the downregulation of survivin expression.Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma.Unfolded protein response inducers tunicamycin and dithiothreitol promote myeloma cell differentiation mediated by XBP-1.Vernodalol mediates antitumor effects in acute promyelocytic leukemia cells.Effect of NADPH-cytochrome P450 reductase on all-trans-retinoic acid efficacy and cytochrome P450 26A1 expression in human myeloid leukaemia HL-60 cells.

P2860

Q28393380-8F0ED8E4-EB6A-4A3B-A23A-AB8CDA75247C Q28538642-239167DB-63E4-4B38-94B5-7AF53E9A2FC5 Q28541829-E546EC71-C612-4C3A-9EF1-445C4865C712 Q33720319-7DA68608-3A2C-4D98-970E-87BA58BB0726 Q34486392-6D6D2F56-F1B8-4C5E-A174-406416982EC1 Q36074014-A492013D-9917-4E94-B113-77DAFCC8DB03 Q36250532-BB158CE1-1FC7-4615-B07F-B37EA14C6CD7 Q37062037-465D2E00-9F7A-4703-84DA-D1BD14926D0F Q37154434-5CFAE41A-5646-4B23-BF96-5C46897710D5 Q37477796-67D4885D-3D4E-4A90-9172-C13DD4A267C8 Q37660329-98F14DAF-F9A2-4B49-B621-702C1FC78D17 Q38042324-FCC8F505-0BF7-496B-9881-3A9C7737B953 Q38066478-4A8704F9-9CD8-4D97-8D13-40E3505E0269 Q39034077-E033FFE8-D6DC-472A-9FA8-42443D18F982 Q39187156-DF067D0B-F5E4-433B-8493-32C2E57036B6 Q39247959-08379CB8-B763-4639-ADBA-F62BDCF67574 Q39298072-96E1CCDF-0588-46E1-9382-CDF9443FF9F5 Q40973364-260C8B2B-4A3D-4E42-9835-446D2A50AFF7 Q44522462-C4D42A0C-9318-4E09-8983-F01AD767FDC1 Q49706476-4416B750-59F8-4741-931E-6FBA54D295A2 Q51670242-A8004774-E686-4A6F-8A95-9F4BE85A6734

P2860

Advances in therapies for acute promyelocytic leukemia.

http://www.wikidata.org/entity/Q37905921

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Advances in therapies for acute promyelocytic leukemia.

@en

Advances in therapies for acute promyelocytic leukemia.

@nl

type

label

Advances in therapies for acute promyelocytic leukemia.

@en

Advances in therapies for acute promyelocytic leukemia.

@nl

prefLabel

Advances in therapies for acute promyelocytic leukemia.

@en

Advances in therapies for acute promyelocytic leukemia.

@nl

P1433

Q37905921-4DD88D5B-83AD-4913-A1A5-5E4FD070057D

P1476

Q37905921-824C50E3-4335-426A-87B0-F3C1C57E54F6

P2093

Q37905921-344422A7-2ED7-4B08-8A07-9E79B3D5B7B7

Q37905921-C6150C2E-C2E8-4B27-8BA3-47F6DD1C80B4

Q37905921-D45A75F0-C962-44F9-A31D-8C1404C55D49

Q37905921-E651B8AE-4D57-497B-AEFC-A5F04D385623

P2860

Q37905921-04C91B6F-253A-45FB-A6EF-5D513B50B4FF

Q37905921-0595DA68-569E-4687-A914-AF3A1010051F

Q37905921-11F2483A-B064-4C3D-9D81-D361E694A5D6

Q37905921-159BF38B-DB28-4CD2-AFE8-589A5C079367

Q37905921-1869FA0A-65F7-4DDA-948B-5142CAB1E9AA

Q37905921-1DF4A275-9F5B-4783-939E-1F8F0437DFC1

Q37905921-27626227-737E-4EF6-ACA4-E5FCBA8711AD

Q37905921-2D83AD16-F63F-4760-917D-5B09A5215003

Q37905921-2EDD8475-DB4D-4C0E-9112-07254BF14DE9

Q37905921-3307982E-377C-4112-AE11-AC9DD6F13618

P304

Q37905921-77B110C8-205C-4ED0-9173-35C045026538

P31

Q37905921-6D508CCC-0E97-4CEF-862F-91FFF5E7B9C2

P356

Q37905921-E5BCD4BA-1D44-4569-A043-93290D03E9F4

P433

Q37905921-D8C5E9A6-9C22-4567-AF22-5E17875B09FF

P478

Q37905921-8C977226-048E-4FC6-9672-67FB63CDE161

P577

Q37905921-9BE8D5B3-441F-4129-950F-0A79E96C10F7

P5875

Q37905921-FB4025B1-D88D-4352-B66D-1566CEF1B269

P698

Q37905921-1D53B9A6-84EF-48E6-99EA-8D960290E4EA

P921

Q37905921-8E64D29A-0EAB-4E1B-8E1F-AD0D904DB629

P356

J.1349-7006.2011.02045.X

P1433

P1476

Advances in therapies for acute promyelocytic leukemia.

@en

P2093

Koichi Akashi

http://www.w3.org/2001/XMLSchema#string

Mine Harada

http://www.w3.org/2001/XMLSchema#string

Tomohiko Kamimura

http://www.w3.org/2001/XMLSchema#string

Toshihiro Miyamoto

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

All-trans-retinoic acid in acute promyelocytic leukemia

Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.

Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.

P304

1929-1937

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1349-7006.2011.02045.X

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51522712

http://www.w3.org/2001/XMLSchema#string

P698

21790894

http://www.w3.org/2001/XMLSchema#string

P921